Staging for prostate cancer: Time to incorporate pretreatment prostate-specific antigen and gleason score?

Cancer

Volumn 109, Issue 2, 2007, Pages 213-220

  Roach III, Mack ^a,b   Weinberg, Vivian ^a,b   Sandler, Howard ^c   Thompson, Ian ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

American Joint Committee on Cancer staging system; Long term survival; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 33846308888     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22403     Document Type: Article

References (41)

1. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003; 170:1798-1803.
2. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
3. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [see comments]. JAMA. 1998;280:975-980.
4. Roach M, Lu J, Pilepich M, et al. Four prognostic groups predict long term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
5. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
6. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998;16: 3380-3385.
7. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-3359.
8. Roach III M, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003;61:730-735.
9. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
10. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003;169:1320-1324.
11. Williams SG, Duchesne GM, Millar JL, Pratt GR. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1082-1087.
12. Kwan W, Pickles T, Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1040-1046.
13. Weinberg V, Roach M, McLaughlin P, Sandler H.A new staging system for prostate cancer based on T-stage, Gleason score and PSA improves the prediction of survival. Paper presented at: Proceedings of the American Society for Therapeutic Radiology and Oncology, November 4-8, 2001; San Francisco, Calif.
14. American Society for Therapeutic Radiology and Oncology. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
15. Kaplan EL, Meier P. Non-parameteric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
17. Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Cancer Staging Manual. 5 ed. Philadelphia: Lippincott-Raven; 1998.
18. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian Phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:15-23.
19. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 Pt 2):S21-S25; discussion, S26-S27.
20. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 58:25-33.
21. Lattanzi JP, Hanlon AL, Hanks GE. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group. Int J Radiat Oncol Biol Phys. 1997;38:569-573.
22. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-385.
23. D'Amico AV, Keshaviah A, Manola J, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:581-587.
24. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726-3732.
25. Zietman AL, Chung CS, Coen JJ, Shipley WU. Ten-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004;171:210-214.
26. Selek U, Lee A, Levy L, Kuban DA. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:963-967.
27. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444-452.
28. Potters L, Morgenstern C, Mullen EE, Fearn P Jassal A, Kattan M. Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer. Paper presented at: Proceeding of the American Society for Therapeutic Radiology and Oncology; October 3-7, 2004; Atlanta, Ga.
29. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer [see comments]. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
30. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
31. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944-952.
32. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915-928.
33. Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys. 2004;58:11-18.
34. Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002;52:664-673.
35. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 1999;46:397-402.
36. Speight JL, Weinberg VK, McLaughlin PW, Roach M, Sandler HM.3D conformal radiotherapy improves PSA failure rates for intermediate risk patients at conventional doses. Paper presented at: Proceedings of the American Society for Therapeutic Radiology and Oncology; October 31-November 4, 1999; San Antonio, Tex.
37. Roach III M, Chen A, Song J, Diaz A, Presti J Jr, Carroll P. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol. 2000;18:108-114.
38. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314-1322.
39. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18:1164-1172.
40. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol. 2002;168: 1994-1999.
41. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002;59:560-565.